is there a semaglutide shortage FDA crackdown on off-brand Ozempic products set to take effect, threatening supply and access for many Explainer: What's behind the scramble

Compounded GLP-1 availability concerns

Many patients report mild contour improvements , minimal downtime, and a relatively comfortable recovery experience

doi: 10.1007/s11270-023-06861-0 182 MokryD

Here is the timeline of average weight loss: 12 weeks: -20.12 pounds 24 weeks: -35.67 pounds 36 weeks: -47.33 pounds 52 weeks (1 year): -52.28 pounds 72 weeks (18 months): -62.79 pounds (-26.54% body weight) These are averages, which means individual results varied

However, allowing more than 7 days between doses can lower your medication level in the bloodstream, reducing appetite suppression and potentially slowing weight loss temporarily

Key Takeaway Orforglipron is poised to become the first oral, non-peptide GLP-1 receptor agonist approved for obesity treatment